FRI0187 A Randomized Crossover Comparison of Injection Site Pain with 40 Mg/0.8 Ml and 40 mg/0.4 ml Formulations of Adalimumab in Patients with Rheumatoid Arthritis

Background A new 40 mg/0.4 mL formulation of adalimumab was developed that has fewer excipients, a smaller volume, and a delivery presentation with a smaller gauge needle than the current 40 mg/0.8 mL formulation. Objectives Evaluate injection site–related pain, safety, and tolerability of the new and current formulations of adalimumab in patients with rheumatoid arthritis (RA). Methods In 2 identically designed, phase 2, randomized, …